| Literature DB >> 1314232 |
E F Smit1, E G de Vries, H Timmer-Bosscha, L F de Leij, J W Oosterhuis, R J Scheper, J J Weening, P E Postmus, N H Mulder.
Abstract
Three cell lines derived from small-cell lung carcinoma (SCLC) tumors of patients who had no clinical response after treatment with a multi-drug regimen were compared to 3 cell lines derived from tumors of patients who, upon treatment, showed a complete clinical response. These 2 groups of cell lines were considered to represent the in vitro counterparts of the 2 extremes of the clinical spectrum of sensitivity for chemotherapeutic drugs in small-cell lung cancer. To assess whether the in vivo (in)sensitivity of a tumor to a certain drug regimen is retained in vitro, the cell lines were tested for drug sensitivity using the microtiter-well tetrazolium assay and the results were compared with the in vivo data. No correlation was found. Since in vitro models using cell lines are based on the assumption that a cell line reflects the properties of the tumor from which it is derived, several additional parameters such as MAb staining against different SCLC-associated antigens and DNA content were analyzed in the biopsies and the cell lines. The results showed that selection of discrete tumor-cell populations in vitro occurs. Results of in vitro chemosensitivity testing for individual SCLC patients should be interpreted with caution.Entities:
Mesh:
Substances:
Year: 1992 PMID: 1314232 DOI: 10.1002/ijc.2910510115
Source DB: PubMed Journal: Int J Cancer ISSN: 0020-7136 Impact factor: 7.396